<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29670046</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>09</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Apr</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1232</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms19041232</ELocationID>
        <Abstract>
          <AbstractText>Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib), a soluble VEGF decoy receptor (aflibercept), and a humanized monoclonal antibody of VEGF receptor 2 (VEGFR2) (ramucirumab) have been approved for cancer therapy. Although many types of VEGF pathway inhibitors can improve survival in most cancer patients, some patients have little or no beneficial effect from them. The primary or acquired resistance towards many oncological drugs, including anti-VEGF inhibitors, is a common problem in cancer treatment. This review summarizes the proposed alternative mechanisms of angiogenesis other than the VEGF pathway. These mechanisms are involved in the development of resistance to anti-VEGF therapies in cancer patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Itatani</LastName>
            <ForeName>Yoshiro</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. itatani@kuhp.kyoto-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawada</LastName>
            <ForeName>Kenji</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0003-4336-6937</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. kkawada@kuhp.kyoto-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yamamoto</LastName>
            <ForeName>Takamasa</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. masayama@kuhp.kyoto-u.ac.jp.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Moores Cancer Center, University of California San Diego, San Diego, CA 92093, USA. masayama@kuhp.kyoto-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sakai</LastName>
            <ForeName>Yoshiharu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan. ysakai@kuhp.kyoto-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>04</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anti-angiogenic therapy</Keyword>
        <Keyword MajorTopicYN="N">resistance to anti-VEGF</Keyword>
        <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflicts of interest exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>9</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29670046</ArticleId>
        <ArticleId IdType="pmc">PMC5979390</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms19041232</ArticleId>
        <ArticleId IdType="pii">ijms19041232</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971;285:1182–1186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4938153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987;235:442–447. doi: 10.1126/science.2432664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.2432664</ArticleId>
            <ArticleId IdType="pubmed">2432664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann. Surg. 1972;175:409–416. doi: 10.1097/00000658-197203000-00014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000658-197203000-00014</ArticleId>
            <ArticleId IdType="pmc">PMC1355186</ArticleId>
            <ArticleId IdType="pubmed">5077799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309–1312. doi: 10.1126/science.2479987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.2479987</ArticleId>
            <ArticleId IdType="pubmed">2479987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309. doi: 10.1126/science.2479986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.2479986</ArticleId>
            <ArticleId IdType="pubmed">2479986</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003;9:669–676. doi: 10.1038/nm0603-669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0603-669</ArticleId>
            <ArticleId IdType="pubmed">12778165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92:735–745. doi: 10.1016/S0092-8674(00)81402-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(00)81402-6</ArticleId>
            <ArticleId IdType="pubmed">9529250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy? Nat. Rev. Cancer. 2008;8:942–956. doi: 10.1038/nrc2524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2524</ArticleId>
            <ArticleId IdType="pubmed">19029957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008;358:2039–2049. doi: 10.1056/NEJMra0706596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra0706596</ArticleId>
            <ArticleId IdType="pmc">PMC4542009</ArticleId>
            <ArticleId IdType="pubmed">18463380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Hooper A.T., Zhong Z., Witte L., Bohlen P., Rafii S., Hicklin D.J. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int. J. Cancer. 2006;119:1519–1529. doi: 10.1002/ijc.21865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.21865</ArticleId>
            <ArticleId IdType="pubmed">16671089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Zhong Z., Huber J., Bassi R., Finnerty B., Corcoran E., Li H., Navarro E., Balderes P., Jimenez X., et al.  Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer. Clin. Cancer Res. 2006;12:6573–6584. doi: 10.1158/1078-0432.CCR-06-0831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-06-0831</ArticleId>
            <ArticleId IdType="pubmed">17085673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841–844. doi: 10.1038/362841a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/362841a0</ArticleId>
            <ArticleId IdType="pubmed">7683111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004;350:2335–2342. doi: 10.1056/NEJMoa032691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa032691</ArticleId>
            <ArticleId IdType="pubmed">15175435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006;24:16–24. doi: 10.1200/JCO.2005.02.2574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.02.2574</ArticleId>
            <ArticleId IdType="pubmed">16330672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Staehler M., Negrier S., Chevreau C., Desai A.A., Rolland F., et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 2009;27:3312–3318. doi: 10.1200/JCO.2008.19.5511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2008.19.5511</ArticleId>
            <ArticleId IdType="pubmed">19451442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C.H., Salman P., Gladkov O.A., Kavina A., et al.  Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J. Clin. Oncol. 2010;28:1061–1068. doi: 10.1200/JCO.2009.23.9764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.23.9764</ArticleId>
            <ArticleId IdType="pubmed">20100962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausova J., Macarulla T., Ruff P., van Hazel G.A., Moiseyenko V., Ferry D., et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012;30:3499–3506. doi: 10.1200/JCO.2012.42.8201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.42.8201</ArticleId>
            <ArticleId IdType="pubmed">22949147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilke H., Muro K., Van Cutsem E., Oh S.C., Bodoky G., Shimada Y., Hironaka S., Sugimoto N., Lipatov O., Kim T.Y., et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–1235. doi: 10.1016/S1470-2045(14)70420-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)70420-6</ArticleId>
            <ArticleId IdType="pubmed">25240821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giantonio B.J., Catalano P.J., Meropol N.J., O’Dwyer P.J., Mitchell E.P., Alberts S.R., Schwartz M.A., Benson A.B., 3rd Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007;25:1539–1544. doi: 10.1200/JCO.2006.09.6305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2006.09.6305</ArticleId>
            <ArticleId IdType="pubmed">17442997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232–239. doi: 10.1016/j.ccr.2009.01.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.01.021</ArticleId>
            <ArticleId IdType="pmc">PMC4540346</ArticleId>
            <ArticleId IdType="pubmed">19249681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220–231. doi: 10.1016/j.ccr.2009.01.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.01.027</ArticleId>
            <ArticleId IdType="pmc">PMC2874829</ArticleId>
            <ArticleId IdType="pubmed">19249680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maisonpierre P.C., Suri C., Jones P.F., Bartunkova S., Wiegand S.J., Radziejewski C., Compton D., McClain J., Aldrich T.H., Papadopoulos N., et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60. doi: 10.1126/science.277.5322.55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.277.5322.55</ArticleId>
            <ArticleId IdType="pubmed">9204896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D. Signaling vascular morphogenesis and maintenance. Science. 1997;277:48–50. doi: 10.1126/science.277.5322.48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.277.5322.48</ArticleId>
            <ArticleId IdType="pubmed">9229772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eklund L., Kangas J., Saharinen P. Angiopoietin–Tie signalling in the cardiovascular and lymphatic systems. Clin. Sci. 2017;131:87–103. doi: 10.1042/CS20160129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/CS20160129</ArticleId>
            <ArticleId IdType="pmc">PMC5146956</ArticleId>
            <ArticleId IdType="pubmed">27941161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brindle N.P., Saharinen P., Alitalo K. Signaling and functions of angiopoietin-1 in vascular protection. Circ. Res. 2006;98:1014–1023. doi: 10.1161/01.RES.0000218275.54089.12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.RES.0000218275.54089.12</ArticleId>
            <ArticleId IdType="pmc">PMC2270395</ArticleId>
            <ArticleId IdType="pubmed">16645151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eklund L., Saharinen P. Angiopoietin signaling in the vasculature. Exp. Cell Res. 2013;319:1271–1280. doi: 10.1016/j.yexcr.2013.03.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2013.03.011</ArticleId>
            <ArticleId IdType="pubmed">23500414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helfrich I., Edler L., Sucker A., Thomas M., Christian S., Schadendorf D., Augustin H.G. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin. Cancer Res. 2009;15:1384–1392. doi: 10.1158/1078-0432.CCR-08-1615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-1615</ArticleId>
            <ArticleId IdType="pubmed">19228739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sfiligoi C., de Luca A., Cascone I., Sorbello V., Fuso L., Ponzone R., Biglia N., Audero E., Arisio R., Bussolino F., et al.  Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int. J. Cancer. 2003;103:466–474. doi: 10.1002/ijc.10851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.10851</ArticleId>
            <ArticleId IdType="pubmed">12478661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moon W.S., Rhyu K.H., Kang M.J., Lee D.G., Yu H.C., Yeum J.H., Koh G.Y., Tarnawski A.S. Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma? Mod. Pathol. 2003;16:552–557. doi: 10.1097/01.MP.0000071841.17900.69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.MP.0000071841.17900.69</ArticleId>
            <ArticleId IdType="pubmed">12808060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa M., Yamamoto H., Nagano H., Miyake Y., Sugita Y., Hata T., Kim B.N., Ngan C.Y., Damdinsuren B., Ikenaga M., et al.  Hepatic expression of ANG2 RNA in metastatic colorectal cancer. Hepatology. 2004;39:528–539. doi: 10.1002/hep.20048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.20048</ArticleId>
            <ArticleId IdType="pubmed">14768007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goede V., Coutelle O., Neuneier J., Reinacher-Schick A., Schnell R., Koslowsky T.C., Weihrauch M.R., Cremer B., Kashkar H., Odenthal M., et al.  Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br. J. Cancer. 2010;103:1407–1414. doi: 10.1038/sj.bjc.6605925.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6605925</ArticleId>
            <ArticleId IdType="pmc">PMC2990609</ArticleId>
            <ArticleId IdType="pubmed">20924372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rigamonti N., Kadioglu E., Keklikoglou I., Wyser Rmili C., Leow C.C., De Palma M. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 2014;8:696–706. doi: 10.1016/j.celrep.2014.06.059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.06.059</ArticleId>
            <ArticleId IdType="pubmed">25088418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown J.L., Cao Z.A., Pinzon-Ortiz M., Kendrew J., Reimer C., Wen S., Zhou J.Q., Tabrizi M., Emery S., McDermott B., et al.  A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther. 2010;9:145–156. doi: 10.1158/1535-7163.MCT-09-0554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-09-0554</ArticleId>
            <ArticleId IdType="pubmed">20053776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kienast Y., Klein C., Scheuer W., Raemsch R., Lorenzon E., Bernicke D., Herting F., Yu S., The H.H., Martarello L., et al.  Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin. Cancer Res. 2013;19:6730–6740. doi: 10.1158/1078-0432.CCR-13-0081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0081</ArticleId>
            <ArticleId IdType="pubmed">24097868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scholz A., Harter P.N., Cremer S., Yalcin B.H., Gurnik S., Yamaji M., Di Tacchio M., Sommer K., Baumgarten P., Bahr O., et al.  Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol. Med. 2016;8:39–57. doi: 10.15252/emmm.201505505.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201505505</ArticleId>
            <ArticleId IdType="pmc">PMC4718155</ArticleId>
            <ArticleId IdType="pubmed">26666269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>A Study of Vanucizumab (RO5520985) alone or in Combination with Atezolizumab in Participants with Locally Advanced or Metastatic Solid Tumors.  [(accessed on 5 April 2018)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT01688206.</Citation>
        </Reference>
        <Reference>
          <Citation>A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX with Bevacizmab and FOLFOX in Participants with Untreated Metastatic Colorectal Cancer (McCAVE)  [(accessed on 5 April 2018)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02141295.</Citation>
        </Reference>
        <Reference>
          <Citation>Evans J., Catalano R.D., Morgan K., Critchley H.O., Millar R.P., Jabbour H.N. Prokineticin 1 signaling and gene regulation in early human pregnancy. Endocrinology. 2008;149:2877–2887. doi: 10.1210/en.2007-1633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2007-1633</ArticleId>
            <ArticleId IdType="pmc">PMC2696030</ArticleId>
            <ArticleId IdType="pubmed">18339712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin C., Balasubramanian R., Dwyer A.A., Au M.G., Sidis Y., Kaiser U.B., Seminara S.B., Pitteloud N., Zhou Q.Y., Crowley W.F. The Role of the Prokineticin 2 Pathway in Human Reproduction: Evidence from the Study of Human and Murine Gene Mutations. Endocr. Rev. 2011;32:225–246. doi: 10.1210/er.2010-0007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/er.2010-0007</ArticleId>
            <ArticleId IdType="pmc">PMC3365793</ArticleId>
            <ArticleId IdType="pubmed">21037178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeCouter J., Lin R., Tejada M., Frantz G., Peale F., Hillan K.J., Ferrara N. The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc. Natl. Acad. Sci. USA. 2003;100:2685–2690. doi: 10.1073/pnas.0337667100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0337667100</ArticleId>
            <ArticleId IdType="pmc">PMC151401</ArticleId>
            <ArticleId IdType="pubmed">12604792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., Blanchard D., Bais C., Peale F.V., van Bruggen N., et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007;450:825–831. doi: 10.1038/nature06348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature06348</ArticleId>
            <ArticleId IdType="pubmed">18064003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong C., Qu X., Tan M., Meng Y.G., Ferrara N. Characterization and regulation of bv8 in human blood cells. Clin. Cancer Res. 2009;15:2675–2684. doi: 10.1158/1078-0432.CCR-08-1954.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-1954</ArticleId>
            <ArticleId IdType="pubmed">19336519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung A.S., Wu X., Zhuang G., Ngu H., Kasman I., Zhang J., Vernes J.M., Jiang Z., Meng Y.G., Peale F.V., et al.  An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 2013;19:1114–1123. doi: 10.1038/nm.3291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3291</ArticleId>
            <ArticleId IdType="pubmed">23913124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris K.T., Khan H., Ahmad A., Weston L.L., Nofchissey R.A., Pinchuk I.V., Beswick E.J. G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration. Br. J. Cancer. 2014;110:1211–1220. doi: 10.1038/bjc.2013.822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.822</ArticleId>
            <ArticleId IdType="pmc">PMC3950854</ArticleId>
            <ArticleId IdType="pubmed">24448357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mroczko B., Groblewska M., Wereszczynska-Siemiatkowska U., Kedra B., Konopko M., Szmitkowski M. The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin. Chim. Acta. 2006;371:143–147. doi: 10.1016/j.cca.2006.02.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cca.2006.02.037</ArticleId>
            <ArticleId IdType="pubmed">16603145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krzystek-Korpacka M., Diakowska D., Kapturkiewicz B., Bebenek M., Gamian A. Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett. 2013;337:107–114. doi: 10.1016/j.canlet.2013.05.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2013.05.033</ArticleId>
            <ArticleId IdType="pubmed">23726839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roland C.L., Dineen S.P., Lynn K.D., Sullivan L.A., Dellinger M.T., Sadegh L., Sullivan J.P., Shames D.S., Brekken R.A. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol. Cancer Ther. 2009;8:1761–1771. doi: 10.1158/1535-7163.MCT-09-0280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-09-0280</ArticleId>
            <ArticleId IdType="pubmed">19567820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piao Y., Liang J., Holmes L., Zurita A.J., Henry V., Heymach J.V., de Groot J.F. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol. 2012;14:1379–1392. doi: 10.1093/neuonc/nos158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nos158</ArticleId>
            <ArticleId IdType="pmc">PMC3480262</ArticleId>
            <ArticleId IdType="pubmed">22965162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cetin B., Kaplan M.A., Berk V., Ozturk S.C., Benekli M., Isikdogan A., Ozkan M., Coskun U., Buyukberber S. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents. Asian Pac. J. Cancer Prev. 2012;13:1059–1063. doi: 10.7314/APJCP.2012.13.3.1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7314/APJCP.2012.13.3.1059</ArticleId>
            <ArticleId IdType="pubmed">22631638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Botta C., Barbieri V., Ciliberto D., Rossi A., Rocco D., Addeo R., Staropoli N., Pastina P., Marvaso G., Martellucci I., et al.  Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol. Ther. 2013;14:469–475. doi: 10.4161/cbt.24425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cbt.24425</ArticleId>
            <ArticleId IdType="pmc">PMC3813562</ArticleId>
            <ArticleId IdType="pubmed">23760488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dirican A., Varol U., Kucukzeybek Y., Alacacioglu A., Erten C., Somali I., Can A., Demir L., Bayoglu I.V., Akyol M., et al.  Treatment of metastatic colorectal cancer with or without bevacizumab: Can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab? Asian Pac. J. Cancer Prev. 2014;15:4781–4786. doi: 10.7314/APJCP.2014.15.12.4781.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7314/APJCP.2014.15.12.4781</ArticleId>
            <ArticleId IdType="pubmed">24998541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Passardi A., Scarpi E., Cavanna L., Dall’Agata M., Tassinari D., Leo S., Bernardini I., Gelsomino F., Tamberi S., Brandes A.A., et al.  Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget. 2016;7:33210–33219. doi: 10.18632/oncotarget.8901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.8901</ArticleId>
            <ArticleId IdType="pmc">PMC5078087</ArticleId>
            <ArticleId IdType="pubmed">27120807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007;25:911–920. doi: 10.1038/nbt1323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt1323</ArticleId>
            <ArticleId IdType="pubmed">17664940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phan V.T., Wu X., Cheng J.H., Sheng R.X., Chung A.S., Zhuang G., Tran C., Song Q., Kowanetz M., Sambrone A., et al.  Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc. Natl. Acad. Sci. USA. 2013;110:6079–6084. doi: 10.1073/pnas.1303302110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1303302110</ArticleId>
            <ArticleId IdType="pmc">PMC3625253</ArticleId>
            <ArticleId IdType="pubmed">23530240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu X., Zhuang G., Yu L., Meng G., Ferrara N. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: Key role of Stat3 signaling. J. Biol. Chem. 2012;287:19574–19584. doi: 10.1074/jbc.M111.326801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.326801</ArticleId>
            <ArticleId IdType="pmc">PMC3365993</ArticleId>
            <ArticleId IdType="pubmed">22528488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kowanetz M., Wu X., Lee J., Tan M., Hagenbeek T., Qu X., Yu L., Ross J., Korsisaari N., Cao T., et al.  Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA. 2010;107:21248–21255. doi: 10.1073/pnas.1015855107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1015855107</ArticleId>
            <ArticleId IdType="pmc">PMC3003076</ArticleId>
            <ArticleId IdType="pubmed">21081700</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y.G., Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. USA. 2009;106:6742–6747. doi: 10.1073/pnas.0902280106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0902280106</ArticleId>
            <ArticleId IdType="pmc">PMC2665197</ArticleId>
            <ArticleId IdType="pubmed">19346489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Curtis V.F., Wang H., Yang P., McLendon R.E., Li X., Zhou Q.Y., Wang X.F. A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. PLoS ONE. 2013;8:e54916.  doi: 10.1371/journal.pone.0054916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0054916</ArticleId>
            <ArticleId IdType="pmc">PMC3553000</ArticleId>
            <ArticleId IdType="pubmed">23372791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ornitz D.M., Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 2015;4:215–266. doi: 10.1002/wdev.176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wdev.176</ArticleId>
            <ArticleId IdType="pmc">PMC4393358</ArticleId>
            <ArticleId IdType="pubmed">25772309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaVallee T.M., Prudovsky I.A., McMahon G.A., Hu X., Maciag T. Activation of the MAP Kinase Pathway by FGF-1 Correlates with Cell Proliferation Induction While Activation of the Src Pathway Correlates with Migration. J. Cell Biol. 1998;141:1647–1658. doi: 10.1083/jcb.141.7.1647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.141.7.1647</ArticleId>
            <ArticleId IdType="pmc">PMC2133001</ArticleId>
            <ArticleId IdType="pubmed">9647656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y., Li X., Eswarakumar V.P., Seger R., Lonai P. Fibroblast growth factor (FGF) signaling through PI 3-kinase and Akt/PKB is required for embryoid body differentiation. Oncogene. 2000;19:3750–3756. doi: 10.1038/sj.onc.1203726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1203726</ArticleId>
            <ArticleId IdType="pubmed">10949929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart K.C., Robertson S.C., Kanemitsu M.Y., Meyer A.N., Tynan J.A., Donoghue D.J. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene. 2000;19:3309–3320. doi: 10.1038/sj.onc.1203650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1203650</ArticleId>
            <ArticleId IdType="pubmed">10918587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chae Y.K., Ranganath K., Hammerman P.S., Vaklavas C., Mohindra N., Kalyan A., Matsangou M., Costa R., Carneiro B., Villaflor V.M., et al.  Inhibition of the fibroblast growth factor receptor (FGFR) pathway: The current landscape and barriers to clinical application. Oncotarget. 2017;8:16052–16074. doi: 10.18632/oncotarget.14109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.14109</ArticleId>
            <ArticleId IdType="pmc">PMC5362545</ArticleId>
            <ArticleId IdType="pubmed">28030802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner N., Grose R. Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer. 2010;10:116–129. doi: 10.1038/nrc2780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2780</ArticleId>
            <ArticleId IdType="pubmed">20094046</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poon R.T., Fan S.T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 2001;19:1207–1225. doi: 10.1200/JCO.2001.19.4.1207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2001.19.4.1207</ArticleId>
            <ArticleId IdType="pubmed">11181687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299–309. doi: 10.1016/j.ccr.2005.09.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2005.09.005</ArticleId>
            <ArticleId IdType="pubmed">16226705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95. doi: 10.1016/j.ccr.2006.11.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2006.11.021</ArticleId>
            <ArticleId IdType="pmc">PMC2748664</ArticleId>
            <ArticleId IdType="pubmed">17222792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopetz S., Hoff P.M., Morris J.S., Wolff R.A., Eng C., Glover K.Y., Adinin R., Overman M.J., Valero V., Wen S., et al.  Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J. Clin. Oncol. 2010;28:453–459. doi: 10.1200/JCO.2009.24.8252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.24.8252</ArticleId>
            <ArticleId IdType="pmc">PMC2815707</ArticleId>
            <ArticleId IdType="pubmed">20008624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsuhashi A., Goto H., Saijo A., Trung V.T., Aono Y., Ogino H., Kuramoto T., Tabata S., Uehara H., Izumi K., et al.  Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat. Commun. 2015;6:8792. doi: 10.1038/ncomms9792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms9792</ArticleId>
            <ArticleId IdType="pmc">PMC4686833</ArticleId>
            <ArticleId IdType="pubmed">26635184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee C.K., Lee M.E., Lee W.S., Kim J.M., Park K.H., Kim T.S., Lee K.Y., Ahn J.B., Chung H.C., Rha S.Y. Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. Am. J. Cancer Res. 2015;5:72–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4300687</ArticleId>
            <ArticleId IdType="pubmed">25628921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andre F., Bachelot T., Campone M., Dalenc F., Perez-Garcia J.M., Hurvitz S.A., Turner N., Rugo H., Smith J.W., Deudon S., et al.  Targeting FGFR with dovitinib (TKI258): Preclinical and clinical data in breast cancer. Clin. Cancer Res. 2013;19:3693–3702. doi: 10.1158/1078-0432.CCR-13-0190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0190</ArticleId>
            <ArticleId IdType="pubmed">23658459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allen E., Walters I.B., Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin. Cancer Res. 2011;17:5299–5310. doi: 10.1158/1078-0432.CCR-10-2847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-2847</ArticleId>
            <ArticleId IdType="pmc">PMC3156934</ArticleId>
            <ArticleId IdType="pubmed">21622725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burbridge M.F., Bossard C.J., Saunier C., Fejes I., Bruno A., Leonce S., Ferry G., Da Violante G., Bouzom F., Cattan V., et al.  S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol. Cancer Ther. 2013;12:1749–1762. doi: 10.1158/1535-7163.MCT-13-0075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-13-0075</ArticleId>
            <ArticleId IdType="pubmed">23804704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semrad T.J., Kim E.J., Tanaka M.S., Sands J., Roberts C., Burich R.A., Li Y., Gandara D.R., Lara P., Mack P.C. Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. Cancer Treat. Res. Commun. 2017;10:21–26. doi: 10.1016/j.ctarc.2016.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctarc.2016.12.002</ArticleId>
            <ArticleId IdType="pmc">PMC5519297</ArticleId>
            <ArticleId IdType="pubmed">28736761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Norden A.D., Schiff D., Ahluwalia M.S., Lesser G.J., Nayak L., Lee E.Q., Rinne M.L., Muzikansky A., Dietrich J., Purow B., et al.  Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J. Neurooncol. 2015;121:297–302. doi: 10.1007/s11060-014-1631-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-014-1631-y</ArticleId>
            <ArticleId IdType="pubmed">25338318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voronov E., Shouval D.S., Krelin Y., Cagnano E., Benharroch D., Iwakura Y., Dinarello C.A., Apte R.N. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA. 2003;100:2645–2650. doi: 10.1073/pnas.0437939100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0437939100</ArticleId>
            <ArticleId IdType="pmc">PMC151394</ArticleId>
            <ArticleId IdType="pubmed">12598651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber A., Wasiliew P., Kracht M. Interleukin-1 (IL-1) pathway. Sci. Signal. 2010;3 doi: 10.1126/scisignal.3105cm1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.3105cm1</ArticleId>
            <ArticleId IdType="pubmed">20086235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saijo Y., Tanaka M., Miki M., Usui K., Suzuki T., Maemondo M., Hong X., Tazawa R., Kikuchi T., Matsushima K., et al.  Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: In vivo analysis of tumor-stromal interaction. J. Immunol. 2002;169:469–475. doi: 10.4049/jimmunol.169.1.469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.169.1.469</ArticleId>
            <ArticleId IdType="pubmed">12077278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thornton R.D., Lane P., Borghaei R.C., Pease E.A., Caro J., Mochan E. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Pt 1Biochem. J. 2000;350:307–312. doi: 10.1042/bj3500307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/bj3500307</ArticleId>
            <ArticleId IdType="pmc">PMC1221256</ArticleId>
            <ArticleId IdType="pubmed">10926858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbone C., Moccia T., Zhu C., Paradiso G., Budillon A., Chiao P.J., Abbruzzese J.L., Melisi D. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin. Cancer Res. 2011;17:5822–5832. doi: 10.1158/1078-0432.CCR-11-1185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-1185</ArticleId>
            <ArticleId IdType="pmc">PMC3178272</ArticleId>
            <ArticleId IdType="pubmed">21737511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbone C., Tamburrino A., Piro G., Boschi F., Cataldo I., Zanotto M., Mina M.M., Zanini S., Sbarbati A., Scarpa A., et al.  Combined inhibition of IL1, CXCR1/2, and TGFbeta signaling pathways modulates in-vivo resistance to anti-VEGF treatment. Anticancer Drugs. 2016;27:29–40. doi: 10.1097/CAD.0000000000000301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CAD.0000000000000301</ArticleId>
            <ArticleId IdType="pubmed">26473526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heldin C.-H. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun. Signal. 2013;11:97. doi: 10.1186/1478-811X-11-97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1478-811X-11-97</ArticleId>
            <ArticleId IdType="pmc">PMC3878225</ArticleId>
            <ArticleId IdType="pubmed">24359404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montmayeur J.P., Valius M., Vandenheede J., Kazlauskas A. The platelet-derived growth factor beta receptor triggers multiple cytoplasmic signaling cascades that arrive at the nucleus as distinguishable inputs. J. Biol. Chem. 1997;272:32670–32678. doi: 10.1074/jbc.272.51.32670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.272.51.32670</ArticleId>
            <ArticleId IdType="pubmed">9405485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francia G., Emmenegger U., Kerbel R.S. Tumor-associated fibroblasts as “Trojan Horse” mediators of resistance to anti-VEGF therapy. Cancer Cell. 2009;15:3–5. doi: 10.1016/j.ccr.2008.12.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2008.12.011</ArticleId>
            <ArticleId IdType="pubmed">19111874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crawford Y., Kasman I., Yu L., Zhong C., Wu X., Modrusan Z., Kaminker J., Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2009;15:21–34. doi: 10.1016/j.ccr.2008.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2008.12.004</ArticleId>
            <ArticleId IdType="pubmed">19111878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roskoski R., Jr. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem. Biophys. Res. Commun. 2007;356:323–328. doi: 10.1016/j.bbrc.2007.02.156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2007.02.156</ArticleId>
            <ArticleId IdType="pubmed">17367763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rock E.P., Goodman V., Jiang J.X., Mahjoob K., Verbois S.L., Morse D., Dagher R., Justice R., Pazdur R. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12:107–113. doi: 10.1634/theoncologist.12-1-107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.12-1-107</ArticleId>
            <ArticleId IdType="pubmed">17227905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FDA Approves Sunitinib Malate for Adjuvant Treatment of Renal Cell Carcinoma.  [(accessed on 16 November 2017)]; Available online:  https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm585686.htm.</Citation>
        </Reference>
        <Reference>
          <Citation>Hainsworth J.D., Spigel D.R., Sosman J.A., Burris H.A., 3rd, Farley C., Cucullu H., Yost K., Hart L.L., Sylvester L., Waterhouse D.M., et al.  Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: A phase I/II trial. Clin. Genitourin. Cancer. 2007;5:427–432. doi: 10.3816/CGC.2007.n.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3816/CGC.2007.n.030</ArticleId>
            <ArticleId IdType="pubmed">18272024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., Persico M.G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. USA. 1991;88:9267–9271. doi: 10.1073/pnas.88.20.9267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.88.20.9267</ArticleId>
            <ArticleId IdType="pmc">PMC52695</ArticleId>
            <ArticleId IdType="pubmed">1924389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 1994;269:25646–25654.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7929268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820–827. doi: 10.1038/nature04186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature04186</ArticleId>
            <ArticleId IdType="pmc">PMC2945882</ArticleId>
            <ArticleId IdType="pubmed">16341007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y., Tu C., Zhao Y., Liu H., Zhang S. Placental growth factor enhances angiogenesis in human intestinal microvascular endothelial cells via PI3K/Akt pathway: Potential implications of inflammation bowel disease. Biochem. Biophys. Res. Commun. 2016;470:967–974. doi: 10.1016/j.bbrc.2016.01.073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2016.01.073</ArticleId>
            <ArticleId IdType="pubmed">26775845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bagley R.G., Ren Y., Weber W., Yao M., Kurtzberg L., Pinckney J., Bangari D., Nguyen C., Brondyk W., Kaplan J., et al.  Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin. Cancer Res. 2011;17:976–988. doi: 10.1158/1078-0432.CCR-10-2687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-2687</ArticleId>
            <ArticleId IdType="pubmed">21343374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willett C.G., Duda D.G., di Tomaso E., Boucher Y., Ancukiewicz M., Sahani D.V., Lahdenranta J., Chung D.C., Fischman A.J., Lauwers G.Y., et al.  Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J. Clin. Oncol. 2009;27:3020–3026. doi: 10.1200/JCO.2008.21.1771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2008.21.1771</ArticleId>
            <ArticleId IdType="pmc">PMC2702234</ArticleId>
            <ArticleId IdType="pubmed">19470921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rini B.I., Michaelson M.D., Rosenberg J.E., Bukowski R.M., Sosman J.A., Stadler W.M., Hutson T.E., Margolin K., Harmon C.S., DePrimo S.E., et al.  Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 2008;26:3743–3748. doi: 10.1200/JCO.2007.15.5416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2007.15.5416</ArticleId>
            <ArticleId IdType="pubmed">18669461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carmeliet P., Moons L., Luttun A., Vincenti V., Compernolle V., De Mol M., Wu Y., Bono F., Devy L., Beck H., et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 2001;7:575–583. doi: 10.1038/87904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/87904</ArticleId>
            <ArticleId IdType="pubmed">11329059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., Chorianopoulos E., Liesenborghs L., Koch M., De Mol M., et al.  Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131:463–475. doi: 10.1016/j.cell.2007.08.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.08.038</ArticleId>
            <ArticleId IdType="pubmed">17981115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bais C., Wu X., Yao J., Yang S., Crawford Y., McCutcheon K., Tan C., Kolumam G., Vernes J.M., Eastham-Anderson J., et al.  PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell. 2010;141:166–177. doi: 10.1016/j.cell.2010.01.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.01.033</ArticleId>
            <ArticleId IdType="pubmed">20371352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lassen U., Chinot O.L., McBain C., Mau-Sorensen M., Larsen V.A., Barrie M., Roth P., Krieter O., Wang K., Habben K., et al.  Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. Neuro Oncol. 2015;17:1007–1015. doi: 10.1093/neuonc/nov019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov019</ArticleId>
            <ArticleId IdType="pmc">PMC5654352</ArticleId>
            <ArticleId IdType="pubmed">25665807</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>FDA Approval for Ziv-Aflibercept.  [(accessed on 3 August 2012)]; Available online:  https://www.cancer.gov/about-cancer/treatment/drugs/fda-ziv-aflibercept.</Citation>
        </Reference>
        <Reference>
          <Citation>Ciombor K.K., Berlin J., Chan E. Aflibercept. Clin. Cancer Res. 2013;19:1920–1925. doi: 10.1158/1078-0432.CCR-12-2911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-2911</ArticleId>
            <ArticleId IdType="pmc">PMC3710732</ArticleId>
            <ArticleId IdType="pubmed">23444216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiron M., Bagley R.G., Pollard J., Mankoo P.K., Henry C., Vincent L., Geslin C., Baltes N., Bergstrom D.A. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol. Cancer Ther. 2014;13:1636–1644. doi: 10.1158/1535-7163.MCT-13-0753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-13-0753</ArticleId>
            <ArticleId IdType="pubmed">24688047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J., Blain S.W., Lo R.S. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295–309. doi: 10.1016/S0092-8674(00)00121-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0092-8674(00)00121-5</ArticleId>
            <ArticleId IdType="pubmed">11057902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998;67:753–791. doi: 10.1146/annurev.biochem.67.1.753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.biochem.67.1.753</ArticleId>
            <ArticleId IdType="pubmed">9759503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts A.B., Sporn M.B., Assoian R.K., Smith J.M., Roche N.S., Wakefield L.M., Heine U.I., Liotta L.A., Falanga V., Kehrl J.H., et al.  Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. USA. 1986;83:4167–4171. doi: 10.1073/pnas.83.12.4167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.83.12.4167</ArticleId>
            <ArticleId IdType="pmc">PMC323692</ArticleId>
            <ArticleId IdType="pubmed">2424019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madri J.A., Pratt B.M., Tucker A.M. Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. J. Cell Biol. 1988;106:1375–1384. doi: 10.1083/jcb.106.4.1375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.106.4.1375</ArticleId>
            <ArticleId IdType="pmc">PMC2115017</ArticleId>
            <ArticleId IdType="pubmed">3283153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrari G., Cook B.D., Terushkin V., Pintucci G., Mignatti P. Transforming growth factor-beta 1 (TGF-β1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J. Cell. Physiol. 2009;219:449–458. doi: 10.1002/jcp.21706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.21706</ArticleId>
            <ArticleId IdType="pmc">PMC2749291</ArticleId>
            <ArticleId IdType="pubmed">19180561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barcellos-Hoff M.H., Akhurst R.J. Transforming growth factor-beta in breast cancer: Too much, too late. Breast Cancer Res. 2009;11:202. doi: 10.1186/bcr2224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr2224</ArticleId>
            <ArticleId IdType="pmc">PMC2687712</ArticleId>
            <ArticleId IdType="pubmed">19291273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 2001;29:117–129. doi: 10.1038/ng1001-117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng1001-117</ArticleId>
            <ArticleId IdType="pubmed">11586292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Derynck R., Goeddel D.V., Ullrich A., Gutterman J.U., Williams R.D., Bringman T.S., Berger W.H. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res. 1987;47:707–712.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3467839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X., Chen Z., Zhu S., Liu T., Wen Y., Su Y., Xi X., Hu Y., Lian L., Liu F. Prognostic value of transforming growth factor-beta in patients with colorectal cancer who undergo surgery: A meta-analysis. BMC Cancer. 2017;17:240.  doi: 10.1186/s12885-017-3215-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-017-3215-7</ArticleId>
            <ArticleId IdType="pmc">PMC5379512</ArticleId>
            <ArticleId IdType="pubmed">28376764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dave H., Shah M., Trivedi S., Shukla S. Prognostic utility of circulating transforming growth factor beta 1 in breast cancer patients. Int. J. Biol. Markers. 2012;27:53–59. doi: 10.5301/JBM.2011.8736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5301/JBM.2011.8736</ArticleId>
            <ArticleId IdType="pubmed">22020368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park S.Y., Piao Y., Jeong K.J., Dong J., de Groot J.F. Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models. Mol. Cancer Ther. 2016;15:2187–2197. doi: 10.1158/1535-7163.MCT-15-0427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-15-0427</ArticleId>
            <ArticleId IdType="pmc">PMC5104278</ArticleId>
            <ArticleId IdType="pubmed">27307601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996;16:4604–4613. doi: 10.1128/MCB.16.9.4604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.16.9.4604</ArticleId>
            <ArticleId IdType="pmc">PMC231459</ArticleId>
            <ArticleId IdType="pubmed">8756616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347–361. doi: 10.1016/S1535-6108(03)00085-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1535-6108(03)00085-0</ArticleId>
            <ArticleId IdType="pubmed">12726861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003;4:915–925. doi: 10.1038/nrm1261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm1261</ArticleId>
            <ArticleId IdType="pubmed">14685170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trusolino L., Bertotti A., Comoglio P.M. MET signalling: Principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2010;11:834–848. doi: 10.1038/nrm3012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3012</ArticleId>
            <ArticleId IdType="pubmed">21102609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahangiri A., De Lay M., Miller L.M., Carbonell W.S., Hu Y.L., Lu K., Tom M.W., Paquette J., Tokuyasu T.A., Tsao S., et al.  Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin. Cancer Res. 2013;19:1773–1783. doi: 10.1158/1078-0432.CCR-12-1281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-1281</ArticleId>
            <ArticleId IdType="pmc">PMC3618605</ArticleId>
            <ArticleId IdType="pubmed">23307858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu K.V., Chang J.P., Parachoniak C.A., Pandika M.M., Aghi M.K., Meyronet D., Isachenko N., Fouse S.D., Phillips J.J., Cheresh D.A., et al.  VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012;22:21–35. doi: 10.1016/j.ccr.2012.05.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2012.05.037</ArticleId>
            <ArticleId IdType="pmc">PMC4068350</ArticleId>
            <ArticleId IdType="pubmed">22789536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakelee H., Zvirbule Z., De Braud F., Kingsley C.D., Mekhail T., Lowe T., Schutte W., Lena H., Lawler W., Braiteh F., et al.  Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. Clin. Lung Cancer. 2017;18:50–59. doi: 10.1016/j.cllc.2016.09.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cllc.2016.09.013</ArticleId>
            <ArticleId IdType="pubmed">27856142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah N., Sukumar S. The Hox genes and their roles in oncogenesis. Nat. Rev. Cancer. 2010;10:361–371. doi: 10.1038/nrc2826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2826</ArticleId>
            <ArticleId IdType="pubmed">20357775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashida T., Takahashi F., Chiba N., Brachtel E., Takahashi M., Godin-Heymann N., Gross K.W., Vivanco M., Wijendran V., Shioda T., et al.  HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc. Natl. Acad. Sci. USA. 2010;107:1100–1105. doi: 10.1073/pnas.0912710107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0912710107</ArticleId>
            <ArticleId IdType="pmc">PMC2824265</ArticleId>
            <ArticleId IdType="pubmed">20080567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhan J., Wang P., Niu M., Wang Y., Zhu X., Guo Y., Zhang H. High expression of transcriptional factor HoxB9 predicts poor prognosis in patients with lung adenocarcinoma. Histopathology. 2015;66:955–965. doi: 10.1111/his.12585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/his.12585</ArticleId>
            <ArticleId IdType="pubmed">25324169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshino Y., Hayashida T., Hirata A., Takahashi H., Chiba N., Ohmura M., Wakui M., Jinno H., Hasegawa H., Maheswaran S., et al.  Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication. Mol. Cancer. 2014;13:102. doi: 10.1186/1476-4598-13-102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-13-102</ArticleId>
            <ArticleId IdType="pmc">PMC4023179</ArticleId>
            <ArticleId IdType="pubmed">24885802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba N., Ozawa Y., Hikita K., Okihara M., Sano T., Tomita K., Takano K., Kawachi S. Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib. Oncol. Rep. 2017;37:2270–2276. doi: 10.3892/or.2017.5474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/or.2017.5474</ArticleId>
            <ArticleId IdType="pubmed">28260092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbone C., Piro G., Simionato F., Ligorio F., Cremolini C., Loupakis F., Ali G., Rossini D., Merz V., Santoro R., et al.  Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clin. Cancer Res. 2017;23:4312–4322. doi: 10.1158/1078-0432.CCR-16-3153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-3153</ArticleId>
            <ArticleId IdType="pubmed">28298545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giancotti F.G., Ruoslahti E. Integrin signaling. Science. 1999;285:1028–1032. doi: 10.1126/science.285.5430.1028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.285.5430.1028</ArticleId>
            <ArticleId IdType="pubmed">10446041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avraamides C.J., Garmy-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer. 2008;8:604–617. doi: 10.1038/nrc2353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2353</ArticleId>
            <ArticleId IdType="pmc">PMC2577722</ArticleId>
            <ArticleId IdType="pubmed">18497750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desgrosellier J.S., Cheresh D.A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer. 2010;10:9–22. doi: 10.1038/nrc2748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2748</ArticleId>
            <ArticleId IdType="pmc">PMC4383089</ArticleId>
            <ArticleId IdType="pubmed">20029421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gotzmann J., Mikula M., Eger A., Schulte-Hermann R., Foisner R., Beug H., Mikulits W. Molecular aspects of epithelial cell plasticity: Implications for local tumor invasion and metastasis. Mutat. Res. 2004;566:9–20. doi: 10.1016/S1383-5742(03)00033-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1383-5742(03)00033-4</ArticleId>
            <ArticleId IdType="pubmed">14706509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foubert P., Varner J.A. Integrins in tumor angiogenesis and lymphangiogenesis. Methods Mol. Biol. 2012;757:471–486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5433623</ArticleId>
            <ArticleId IdType="pubmed">21909928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tchaicha J.H., Reyes S.B., Shin J., Hossain M.G., Lang F.F., McCarty J.H. Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by beta8 integrin. Cancer Res. 2011;71:6371–6381. doi: 10.1158/0008-5472.CAN-11-0991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-0991</ArticleId>
            <ArticleId IdType="pmc">PMC3193578</ArticleId>
            <ArticleId IdType="pubmed">21859829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cordes N., Park C.C. beta1 integrin as a molecular therapeutic target. Int. J. Radiat. Biol. 2007;83:753–760. doi: 10.1080/09553000701639694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/09553000701639694</ArticleId>
            <ArticleId IdType="pubmed">18058364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., Chilvers E.R., Dransfield I., Donnelly S.C., Strieter R., et al.  Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999;5:662–668. doi: 10.1038/9511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/9511</ArticleId>
            <ArticleId IdType="pubmed">10371505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat. Rev. Cancer. 2009;9:665–674. doi: 10.1038/nrc2714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2714</ArticleId>
            <ArticleId IdType="pubmed">19693095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeLay M., Jahangiri A., Carbonell W.S., Hu Y.L., Tsao S., Tom M.W., Paquette J., Tokuyasu T.A., Aghi M.K. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin. Cancer Res. 2012;18:2930–2942. doi: 10.1158/1078-0432.CCR-11-2390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-2390</ArticleId>
            <ArticleId IdType="pmc">PMC3354006</ArticleId>
            <ArticleId IdType="pubmed">22472177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbonell W.S., DeLay M., Jahangiri A., Park C.C., Aghi M.K. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 2013;73:3145–3154. doi: 10.1158/0008-5472.CAN-13-0011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-0011</ArticleId>
            <ArticleId IdType="pmc">PMC4040366</ArticleId>
            <ArticleId IdType="pubmed">23644530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sidorov M., Jahangiri A., Han S.W., De Lay M., Wagner J., Castro B., Flanigan P.M., Imber B.S., Weiss W.A., Aghi M.K. 340 c-Met/beta1 Integrin: A Receptor Complex Driving Invasive Glioblastoma Resistance to Antiangiogenic Therapy. Neurosurgery. 2016;63(Suppl. S1):199–200. doi: 10.1227/01.neu.0000489829.38251.85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/01.neu.0000489829.38251.85</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahangiri A., Nguyen A., Chandra A., Sidorov M.K., Yagnik G., Rick J., Han S.W., Chen W., Flanigan P.M., Schneidman-Duhovny D., et al.  Cross-activating c-Met/beta1 integrin complex drives metastasis and invasive resistance in cancer. Proc. Natl. Acad. Sci. USA. 2017;114:E8685–E8694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5642678</ArticleId>
            <ArticleId IdType="pubmed">28973887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahangiri A., Aghi M.K., Carbonell W.S. beta1 integrin: Critical path to antiangiogenic therapy resistance and beyond. Cancer Res. 2014;74:3–7. doi: 10.1158/0008-5472.CAN-13-1742.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-1742</ArticleId>
            <ArticleId IdType="pmc">PMC4160537</ArticleId>
            <ArticleId IdType="pubmed">24327727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piao Y., Henry V., Tiao N., Park S.Y., Martinez-Ledesma J., Dong J.W., Balasubramaniyan V., de Groot J.F. Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma. Oncotarget. 2017;8:96970–96983. doi: 10.18632/oncotarget.18859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.18859</ArticleId>
            <ArticleId IdType="pmc">PMC5722538</ArticleId>
            <ArticleId IdType="pubmed">29228586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van de Stolpe A., van der Saag P.T. Intercellular adhesion molecule-1. J. Mol. Med. 1996;74:13–33. doi: 10.1007/BF00202069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00202069</ArticleId>
            <ArticleId IdType="pubmed">8834767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39–51. doi: 10.1016/j.cell.2010.03.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2010.03.014</ArticleId>
            <ArticleId IdType="pmc">PMC4994190</ArticleId>
            <ArticleId IdType="pubmed">20371344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castro B.A., Flanigan P., Jahangiri A., Hoffman D., Chen W., Kuang R., De Lay M., Yagnik G., Wagner J.R., Mascharak S., et al.  Macrophage migration inhibitory factor downregulation: A novel mechanism of resistance to anti-angiogenic therapy. Oncogene. 2017;36:3749–3759. doi: 10.1038/onc.2017.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2017.1</ArticleId>
            <ArticleId IdType="pmc">PMC5491354</ArticleId>
            <ArticleId IdType="pubmed">28218903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galon J., Pages F., Marincola F.M., Angell H.K., Thurin M., Lugli A., Zlobec I., Berger A., Bifulco C., Botti G., et al.  Cancer classification using the Immunoscore: A worldwide task force. J. Transl. Med. 2012;10:205. doi: 10.1186/1479-5876-10-205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-10-205</ArticleId>
            <ArticleId IdType="pmc">PMC3554496</ArticleId>
            <ArticleId IdType="pubmed">23034130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi: 10.1126/science.1129139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1129139</ArticleId>
            <ArticleId IdType="pubmed">17008531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pagès F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., et al.  Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. N. Engl. J. Med. 2005;353:2654–2666. doi: 10.1056/NEJMoa051424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa051424</ArticleId>
            <ArticleId IdType="pubmed">16371631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X.D., Hoang A., Zhou L., Kalra S., Yetil A., Sun M., Ding Z., Zhang X., Bai S., German P., et al.  Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunol. Res. 2015;3:1017–1029. doi: 10.1158/2326-6066.CIR-14-0244.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0244</ArticleId>
            <ArticleId IdType="pmc">PMC4561186</ArticleId>
            <ArticleId IdType="pubmed">26014097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuusk T., Albiges L., Escudier B., Grivas N., Haanen J., Powles T., Bex A. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis. 2017;20:205–215. doi: 10.1007/s10456-017-9550-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10456-017-9550-0</ArticleId>
            <ArticleId IdType="pubmed">28401381</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
